MX9704669A - Uso de nebivolol como un antiaterogenico. - Google Patents

Uso de nebivolol como un antiaterogenico.

Info

Publication number
MX9704669A
MX9704669A MX9704669A MX9704669A MX9704669A MX 9704669 A MX9704669 A MX 9704669A MX 9704669 A MX9704669 A MX 9704669A MX 9704669 A MX9704669 A MX 9704669A MX 9704669 A MX9704669 A MX 9704669A
Authority
MX
Mexico
Prior art keywords
alpha
nebivolol
atherogenic
chromanmethanol
iminobis
Prior art date
Application number
MX9704669A
Other languages
English (en)
Other versions
MXPA97004669A (es
Inventor
Didier Robert Guy Gabri L D De
Courcelles
Anne Simone Josephine Lesage
Josepha Eduarda Mari Francisca
Leysen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX9704669A publication Critical patent/MX9704669A/es
Publication of MXPA97004669A publication Critical patent/MXPA97004669A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

Esta invencion se refiere al uso de un derivado de alfa,alfa'-iminobis(metileno)bis[2-cromanmetanol] para la fabricacion de un medicamento para el tratamiento terapéutico o profiláctico de humanos que sufren de, o propensos a, enfermedades y condiciones degenerativas de los sistemas vascular y nervioso, las cuales están asociadas con tension oxidativa.
MXPA/A/1997/004669A 1994-12-28 1997-06-20 Uso de nebivolol como un antiaterogenico MXPA97004669A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28
EP94203775.5 1994-12-28
PCT/EP1995/005174 WO1996019987A1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic

Publications (2)

Publication Number Publication Date
MX9704669A true MX9704669A (es) 1997-09-30
MXPA97004669A MXPA97004669A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
WO1996019987A1 (en) 1996-07-04
US5874461A (en) 1999-02-23
US6075046A (en) 2000-06-13
CN1167418C (zh) 2004-09-22
SI0801564T1 (en) 2002-08-31
SK85697A3 (en) 2000-04-10
EP0801564A1 (en) 1997-10-22
CZ191997A3 (cs) 1999-01-13
ES2176354T3 (es) 2002-12-01
CN1171739A (zh) 1998-01-28
DK0801564T3 (da) 2002-07-15
NO972980D0 (no) 1997-06-26
EP0801564B1 (en) 2002-03-27
NO315687B1 (no) 2003-10-13
DE69526120T2 (de) 2002-11-28
ATE214924T1 (de) 2002-04-15
NZ298074A (en) 2001-01-26
NO972980L (no) 1997-06-26
CZ287513B6 (en) 2000-12-13
KR100264348B1 (ko) 2000-08-16
CA2207333A1 (en) 1996-07-04
CA2207333C (en) 2006-10-17
JPH10511655A (ja) 1998-11-10
SK282144B6 (sk) 2001-11-06
HU226208B1 (en) 2008-06-30
DE69526120D1 (de) 2002-05-02
FI972793A (fi) 1997-06-27
HUT77927A (hu) 1998-11-30
FI118884B (fi) 2008-04-30
FI972793A0 (fi) 1997-06-27
AU4347796A (en) 1996-07-19
AU700364B2 (en) 1999-01-07
PT801564E (pt) 2002-09-30

Similar Documents

Publication Publication Date Title
SI0801564T1 (en) Use of nebivolol as an anti-atherogenic
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
BG107537A (en) Method for the inhibition of human tnf alpha activity and its application
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
EP0923376A4 (en) TREATMENT OF ASTHMA AND RESPIRATORY DISEASES
BG102999A (en) New 2,3-diasubstituted-4-(3h)-quinazolinons
AU2549797A (en) Xanthone analogs for the treatment of infectious diseases
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG105275A (en) Tan-1057 derivatives
BG102707A (en) New triazolopurinpurines, method for their preparation and appplication as medicamentous forms
BG102667A (en) Diosgenine-containing composition
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
IL143382A0 (en) Human adult astrocytes, their preparation and uses thereof
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
AU2392797A (en) Use of benzonaphthalene derivatives for the manufacture of medicaments for the treatment of diseases of the nervous system
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
NZ302670A (en) Use of 2,3-dihydro-imidazo[2,1-b]benzothiazole derivatives to treat degenerative disorders and ageing of the nervous and vascular systems
WO1999021538A3 (de) Verwendung von glykosaminoglykanen zur herstellung von pharmazeutischen zubereitungen zur behandlung von mit diabetes assoziierten augenkrankheiten
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
MX9706931A (es) Derivados de amida de acido-2-ciano-3,5-dihidroxi-hex-2-eno-carboxilico.
BG102864A (en) Application of phosphonic acid esters for the treatment of functional disorders of the brain and depressions